A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.
Clinical trial NCT06611163 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06611163
- Sponsor
- Sun Pharmaceutical Industries Limited
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-03-21
- Primary completion
- 2026-01-21
- Enrollment
- 206
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.